Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat

Cardiovascular Drugs and Therapy

Volumn 28, Issue 4, 2014, Pages 313-322

  Khan, Md Abdul Hye ^a   Neckář, Jan ^a,b   Cummens, Breana ^a   Wahl, Geneva M ^a   Imig, John D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Angiotensin receptor blocker; Heart; Kidney; Metabolic syndrome

Indexed keywords

AZILSARTAN MEDOXOMIL; LIPID; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; CHOLESTEROL; GLUCOSE BLOOD LEVEL; INSULIN; OXADIAZOLE DERIVATIVE; PROTECTIVE AGENT; TRIACYLGLYCEROL;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; GLOMERULUS; GLUCOSE TOLERANCE; HEART INJURY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; KIDNEY INJURY; KOLETSKY RAT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; VASCULAR ENDOTHELIUM; ANALYSIS; ANIMAL; BLOOD; BODY WEIGHT; DISEASE MODEL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HEART; HEART MUSCLE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IN VITRO STUDY; KIDNEY; MESENTERIC ARTERY; OBESITY; PATHOLOGY; PHYSIOLOGY; VASODILATATION; WISTAR KYOTO RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DISEASE MODELS, ANIMAL; HEART; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IN VITRO TECHNIQUES; INSULIN; KIDNEY; MALE; MESENTERIC ARTERIES; MYOCARDIUM; OBESITY; OXADIAZOLES; PROTECTIVE AGENTS; RATS, INBRED WKY; TRIGLYCERIDES; VASODILATION;

EID: 84927170630     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-014-6530-0     Document Type: Article

References (46)

1. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin system. Physiol Rev. 2008;86:747-803.
2. Iwanami J, Mogi M, Iwai M, Horiuchi M. Inhibition of renin-angiotensin system and target organ protection. Hypertens Res. 2009;32:229-37.
3. Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, Numemaker CS. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertens. 2010;55:715-21.
4. Sofue T, Kiyomoto H. Angiotensin II receptor blocker is a renoprotective remedy for metabolic syndrome. Hypertens Res. 2009;32:735-7.
5. Elmarakby AA, Imig JD. Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. Clin Sci Lond. 2010;118:291-301.
6. Weir MR. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease. Postgrad Med. 2009;121:96-103.
7. Wassmann S, Laufs U, Bäumer AT, Müller K, Ahlbory K, Linz W, et al. MHG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertens. 2001;37:1450-7. (Pubitemid 34225391)
8. Vieira Jr JM, Rodrigues LT, Mantovani E, Dellê H, Mattar AL, Malheiros DM, et al. Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease. Nephron Physiol. 2005;101:82-91.
9. Baker WL, White WB. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother. 2011;45:1506-15.
10. Vople M, Savoia C. New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. Integr Blood Press Control. 2012;5:19-25.
11. Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T. Synthesis and angiotensin II receptor antagonist activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazolebioisosteres. J Med Chem. 1996;39:5228-35. (Pubitemid 27010313)
12. Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011;336:801-8.
13. Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens. 2011;29:2476-83.
14. Ye Y, Keyes KT, Zhang CF, Perez-Polo JR, Lin Y, Birnbaum Y. Additive effect of TAK-491, a new angiotensin receptor blocker and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther. 2010;24:107-20.
15. Baumann PQ, Zaman T, McElroy-Yaggy K, Sobel BE. The efficacy and tolerability of azilsartan in mice with left ventricular pressure overload or acute myocardial infarction. J Cardiovasc Pharmacol. 2013;61:437-43.
16. Kusumoto K, Igata H, Ojima M, Tsuboi A, Imanishi M, Yamaguchi F, et al. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol. 2011;669:84-93.
17. Koletsky. Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol. 1975;80:129-42.
18. Ernsberger P, Johnson JL, Rosenthal T, Mirelman D, Koletsky RJ. Therapeutic actions of allylmercaptocaptopril and captopril in a rat model of metabolic syndrome. Am J Hypertens. 2007;20:866-74. (Pubitemid 47176345)
19. Ernsberger P, Koletsky RJ, Friedman JE. Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X. Ann N Y Acad Sci. 1999;892:272-88.
20. Imig JD, Walsh KA, Hye Khan MA, Nagasawa T, Cherian-Shaw M, Shaw SM, et al. Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats. Exp Biol Med. 2012;237:1402-12.
21. Purves RD. Optimum numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC). J Pharmacokinet Biopharm. 1992;20:211-26.
22. Scheen AJ. Management of the metabolic syndrome. Minerva Endocrinol. 2004;29:31-45.
23. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertens. 2011;57:413-20.
24. Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, et al. The comparative effect of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens Greenwich. 2011;13:81-8.
25. Sueta D, Kataoka K, Koibuchi N, Toyama K, Uekawa K, Katayama T, et al. Novel mechanism for disrupted circadial blood pressure rhythm in a rat model of metabolic syndrome-the critical role of angiotensin II. J Am Heart Assoc. 2013;2:e000035.
26. Kurtz TW, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133-43.
27. Galili O, Versari D, Sattler KJ, Olson ML, Mannheim D, McConnell JP, et al. Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am J Physiol Heart Circ Physiol. 2007;292:H904-11.
28. Knight SF, Imig JD. Obesity, insulin resistance, and renal function. Microcirc. 2007;14:349-62. (Pubitemid 47050027)
29. Picchhi A, Gao X, Belmandani S, Potter BJ, Focardi M, Chilian WM, et al. Tumor necrosis factor-α induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res. 2006;99:69-77. (Pubitemid 44297057)
30. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis. 2010;20:140-6.
31. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA. Diagnosis andmanagement of themetabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circ. 2005;112:2735-52. (Pubitemid 41532612)
32. Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag. 2008;4:89-101. (Pubitemid 351460850)
33. Russell JC, Kelly SE, Vine DF, Proctor SD. Irbesartan-mediated reduction of renal and cardiac damage in insulin resistant JCR:LA-cp rats. Br J Pharmacol. 2009;158:1588-96.
34. Lee MH, Song HK, Ko GJ, Kang YS, Han SY, Han KH, et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int. 2008;74:890-900.
35. k) rats: a link to amelioration of hypertrigyceridaemia. Br J Pharmacol. 2010;160:1796-807.
36. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atheroscler. 2009;205:1-8.
37. Ecelbarger CM, Rash A, Sinha RK, Tiwari S. The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat. Mediat Inflamm. 2010;2010:841343.
38. Zhao M, Li Y, Wang J, Ebihara K, Rong X, Hosoda K, et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab. 2011;13:1123-9.
39. Lea J, Cheek D, Thornley-Brown D, Appel L, Agodoa L, Contreras G, et al. AASK Study Investigators. Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis. 2008;51:732-40. (Pubitemid 351626250)
40. Pugsley MK. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc West Pharmacol Soc. 2005;48:35-8. (Pubitemid 43053796)
41. Khan MAH, Imig JD. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. Am J Hypertens. 2011;24:816-21.
42. Mizuno M, Sada T, Kato M, Koike H. Renoprotective effect of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res. 2002;25:271-8. (Pubitemid 34464457)
43. Ishimitsu T, Honda T, Ohno E, Furukata S, Sudo Y, Nakano N, et al. Year-long antihypertensive therapy with candesartan completely prevents development of cardiovascular injuries in spontaneously hypertensive rats. Int Heart J. 2010;51:359-64.
44. Nakamura Y, Suzuki S, Saitoh S, Takeishi Y. New angiotensin II type 1 receptor blocker, azilsartan, attenuates cardiac remodeling after myocardial infarction. Biol Pharm Bull. 2013;36:1326-31.
45. 1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. Am J Physiol Heart Circ Physiol. 2008;294:H853-8.
46. Susic D, Fares H, Frohlich ED. Telmisartan prevents excess-salt-induced exacerbated (malignant) hypertension in spontaneous hypertensive rats. J Cardiovasc Pharmacol Ther. 2013;18:126-32.